| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Multimodal therapies including surgery, chemotherapy, and radiotherapy are necessary for advanced esophageal cancer. However, patients with resistance to chemo or radiotherapy cannot derive benefit from the therapy but suffer side effects. Therefore, detecting resistant genes and mechanisms is essential for tailoring treatment to improve the prognosis.We used a novel method involving transposons to screen and identify drug-resistant genes and radio-resistant genes. The new gene screening technique was useful for detecting candidate of drug-resistant genes in esophageal squamous cell carcinoma. We identified 37 candidate genes responsible for CDDP resistance in the two cell lines derived from ESCC cells. TRIM16 is one of the candidate of CDDP resistant gene. We confirmed TRIM 16 overexpression cell has CDDP resistant using MTT assay and resistance is decreased by knocking down TRIM 16. We also confirmed TRIM 16 overexpression cell has CDDP resistant in vivo xenograft model.
|
